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Objectives: Doxorubicin is commonly used in the treatment of superﬁcial bladder cancer, but more side
effects and shorter intracellular retention time hamper its clinical application. Since lipo-doxorubicin
(Lipodox) has the advantages of longer half-life and lower clearance rate than doxorubicin, it should
improve the efﬁcacy of tumor therapy and reduce the normal tissue toxicity of doxorubicin.
Materials and Methods: In this study, we compared the cytotoxicity of Lipodox and doxorubicin in
different treatment durations on bladder cancer cells by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay. Drug distribution was tracked under ﬂuorescence micro-
scopy. The metabolic rate after treatment was measured by serial ﬂow cytometry. Finally, an in vivo
orthotopic MBT-2 bladder tumor model was established for comparing the differences of therapeutic
efﬁcacy, including tumor weight and survival rate.
Results: The 50% inhibitory concentration (IC50) of doxorubicin and Lipodox for MBT-2 cells was 0.62 mg/
mL and 130 mg/mL, respectively, after 48 hours treatment. Lipo-dox presented higher cytotoxicity than
doxorubicin at 6 hours (93% vs 73%) and 12 hours (93% vs 80%) treatment. After drug treatment, Lipodox
ﬂuorescence distribution was observed mostly in the cell membrane, lysosomes, and nuclei of tumor
cells, while doxorubicin was concentrated in the nuclei. Initial ﬂuorescence intensity of doxorubicin was
27.3 times that of Lipodox (p < 0.001) at time of treatment. The ﬂuorescence intensity of doxorubicin
decreased to 12% after 24 hours culture but that of Lipodox remained at 81%. In an orthotopic model, the
average tumor weight and survival were: control group: 1.0 ± 0.3 g, 25%; doxorubicin treatment group:
0.7 ± 0.05 g, 43%; and Lipodox treatment group: 0.2 ± 0.1 g, 57%.
Conclusion: Our study demonstrated that Lipodox can enhance doxorubicin cytotoxicity in bladder
cancer cells and inhibit tumor growth in orthotopic bladder cancer with improved survival rate.
Therefore, we suggest Lipodox may act as an alternative to doxorubicin in the treatment of local bladder
cancer.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from
Streptomyces peucetius var. caesius, and exerts its antitumor effect
via inhibition of topoisomerase II. Using liposomes as a vehicle for
delivering cytostatic agents was ﬁrst described in the 1960s. Lipo-
somes were conceived as drug delivery systems to modify drugDivision of Urology, Depart-
nal Defense Medical Center,
Taipei 114, Taiwan.
ociation. Published by Elsevier Ta
t al., Comparison of therapeu
doi.org/10.1016/j.urols.2016.0pharmacokinetics and distribution, with the goal of reducing the
toxicity of chemotherapy. These liposomes improve the pharma-
cological properties of some cytostatic agents, allowing for an
increased proportion of the drug to be delivered to the tumor tissue
while substantially reducing the exposure to normal tissues.
Liposomal doxorubicin d doxorubicin hydrochloride encapsu-
lated in liposomes coated with methoxy polyethylene glycol (PEG)
d has shown diminished uptake by the reticuloendothelial im-
mune system, a longer half-life, and theoretically increases lipo-
somal deposition in tumor tissue. In comparison to conventional or
liposomal doxorubicin formulas, the PEGylated liposomal doxoru-
bicin (PLD) has extended blood circulation time, improved treat-
ment localization, and better tolerance than conventionaliwan LLC. This is an open access article under the CC BY-NC-ND license (http://
tic efﬁcacy of lipo-doxorubicin and doxorubicin in treating bladder
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Administration (FDA), PLD has become a major component in the
routine management of epithelial ovarian cancer and AIDS-related
Kaposi's sarcoma.2,3 Doxorubicin has been used as one of the
common intravesical chemotherapeutics for superﬁcial bladder
cancer. Its effectiveness is limited by short duration of tumor con-
tact and affordable drug concentration. Hence, we tried to assess
the potential of lipo-doxorubicin (Lipodox) in treating bladder
cancer as an alternative to doxorubicin.
2. Materials and methods
2.1. Culture of cell lines
Low-grade human TCC TSGH-8301 cells established at our lab-
oratory were cultured in RPMI-1640 medium (Thermo Scientiﬁc
HyClone, Logan, UT, USA), supplemented with 10% fetal bovine
serum and antibiotics. One mouse TCC cell line, MBT-2, was pur-
chased from American Type Culture Collection and also cultured in
RPMI-1640 medium. The cultured cells were incubated in 5% CO2 at
37C.
2.2. Chemicals
Doxorubicin was purchased from Sigma (St. Louis, MO, USA).
Lipodox was generously provided by Don-Yang Pharmaceutical Co.
(Taiwan) without conﬂict of interest in this study.
2.3. Cell viability measurement
Cell viability was determined by 3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide (MTT) assay.4 MBT-2 cells were
seeded in triplicate at 2  104 cells/well on a 96-well plate and
incubated with various concentration of doxorubicin or Lipodox for
2 hours and then themediumwas changed. At 6-hour, 12-hour, and
24-hour intervals, the culture media were removed and MTT
(0.5 mg/mL) was added, followed by incubation at 37C for 3 hours
in a CO2 incubator. After insoluble crystals were completely dis-
solved in dimethyl sulfoxide, the absorbance at 560 nm was
measured using a microplate reader (Thermo Scientiﬁc In-
struments, Salzburg, Austria).
2.4. Fluoroscopic observation of intracellular distribution of
doxorubicin and Lipodox in TCC cells
In and on cellular doxorubicin and Lipodox were studied by
ﬂuorescence microscopy distribution. TSGH-8301 TCC cells were
left in sterilized slides for hours until near conﬂuence. Doxorubicin
(1.74 mg/mL) and Lipodox (20 mg/mL) were added to the medium
and coculture for 2 hours. The mediumwas removed and the slides
treated by 1:1 acetone/methanol solution and rinsed using
phosphate-buffered saline solution. The slides were covered by
microslide in 1:1 glycerol/Q water solution and the cells were
observed for drug ﬂuorescence distribution in intracellular struc-
tures under a ﬂuorescence microscope (Leica DMI6000B, Wetzlar,
Germany).
2.5. Changes of intracellular drug concentration measured by ﬂow
cytometry
Flow cytometry was used to detect the intracellular drug ﬂuo-
rescence intensity at different time periods. MBT-2 tumor cells
were cultured in 24-well microplates and treated by 20 mg/mL
doxorubicin or Lipodox for 2 hours. Then the mediumwas replaced
by drug free RPMI-FCS and the cells were continuously cultured forPlease cite this article in press as: Yu D-S, et al., Comparison of therapeu
cancer, Urological Science (2016), http://dx.doi.org/10.1016/j.urols.2016.048 hours. The cells were harvested at 24-hour and 48-hour in-
tervals and the intracellular drug ﬂuorescence measured by EPICS
XL-MCL ﬂow cytometer (BeckmaneCoulter, Miami, FL, USA) and
analyzed by Expo 32 software. The ﬂuorescence intensity was
compared with the initial ﬂuorescence of tumor cells at 2 hours
after drug treatment and expressed as a percentage ratio of initial
drug ﬂuorescence at 24-hour and 48-hour intervals.
2.6. MBT-2 orthotopic tumor implantation
The animal study received institutional animal care and use
committee approval. MBT-2 tumor cells were subjected to passage
in vitro. Single-cell suspensions were prepared from tissue culture
ﬂasks by trypsinization and adjusted to the required concentration
of 5  106 cells/mL. Mice were anesthetized with a single dose of
intraperitoneal injection of 2, 2, 2-tribromoethanol: 2-methyl-2-
butanol: Q water ¼ 1 g: 2.5 mL: 80 mL mixture (20 mL/g body
weight per mouse) before the study. The bladder was catheterized
via the urethra with a 24-gauge plastic intravenous cannula under
sterile conditions. The bladder was then traumatized by instilling
0.1 mL of a 0.1N HCl solution for 15 seconds, which was neutralized
with 0.1 mL 0.1N KOH and then ﬂushed with sterile saline. The
tumor cell suspension (5  105 cells in 0.1 mL 50% normal mouse
serum) was instilled via the cannula. The urethra was compressed
with a serreﬁne clamp for 30 minutes to prevent premature
bladder evacuation. Under these conditions, macroscopic tumors
usually developed in mice, which resulted in death within 6 weeks
without treatment.
2.7. Intravesical treatment of orthotopic bladder tumors using
doxorubicin and Lipodox
For intravesical therapy, the mice were anesthetized, cathe-
terized, and administered 100 mL doxorubicin or Lipodox (160 mg/
mL) and retained for 1 hour in both groups of mice (n ¼ 7). Treat-
ment began 3 days after MBT-2 tumor implantation, and it was
given twice weekly for a total of six doses. In addition, negative
control mice (n ¼ 12) were only injected with 0.1 mL phosphate-
buffered saline. The activity, body weight, and survival of mice
were monitored daily. After a mouse died, it was frozen and kept in
a deep freeze for further histopathological evaluation until the end
of the study. The wet bladder was resected and weighed till the end
of study. Cumulative survival rates of treated MBT-2-bearing mice
were periodically determined during 60 days of observation and
each study was repeated twice.
2.8. Statistical analysis
Data are presented as mean ± standard error of at least three
independent experiments. For comparisons between three or more
groups, two-way analysis of variance was used followed by the
Student method for multiple pair-wise comparisons. Differences
were considered statistically signiﬁcant at a value of p < 0.05.
3. Results
3.1. Lipodox has higher cytotoxicity than doxorubicin for TCC cells
Comparison of cytotoxicity between doxorubicin and Lipodox
over the period of 12 hours after drug treatment with different
serial concentrations revealed that doxorubicin had higher cyto-
toxicity for MBT-2 tumor cells than Lipodox had (Figure 1). At a cut-
off concentration of 15.6 g/mL, doxorubicin and Lipodox had similar
cytotoxicity inMBT-2 tumor cells at the 12-hourmarkwith viability
of <10%. The lipodox-treated cells presented with persistenttic efﬁcacy of lipo-doxorubicin and doxorubicin in treating bladder
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Figure 1. The cellular viability curves of MBT-2 tumor cells after individual treatment
in serial diluted concentrations by doxorubicin (A) and Lipodox (B) for 2 hours and
monitored at different time intervals.
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treated cells had rebound viability in the range of 5e18%.3.2. Different distribution of doxorubicin and Lipodox in tumor cells
The distribution of both drugs within tumor cells after contact
for 2 hours was different. As shown in Figure 2, the main binding
locations of doxorubicin were in the nuclei and cytoplasmic or-
ganelles (Figures 2A and 2B), while Lipodox mainly bound to the
cellular and nuclear membranes (Figures 2C and 2D).3.3. Longer stasis of Lipodox in tumor cells than doxorubicin
The catabolic rate of each drug in tumor cells was monitored for
48 hours after drug treatment (20 mg/mL). The ﬂuorescence in-
tensity of doxorubicin quickly decayed to 12% of original intensity at
the 24-hour mark (Figure 3) and retained the same level until
48 hours. By contrast, Lipodox retained persistent high ﬂuores-
cence intensity of 81% and 84% at 24 hours (p ¼ 0.04) and 48 hours
(p ¼ 0.001), respectively.3.4. Decreased tumor volume and prolonged survival in Lipodox-
treated compared with doxorubicin-treated mice
The wet weight of the orthotopic bladder tumor harvested
60 days after treatment demonstrated a signiﬁcant difference be-
tween doxorubicin and Lipodox treatment groups when compared
with the control group mice (0.73 ± 0.01 g vs 0.20 ± 0.10 g vs
1.02 ± 0.28 g; Figures 4A and 4B). Lipodox treatment demonstrated
most effective therapeutic efﬁcacy against MBT-2 tumor growth
with tumor volume reduction of ~80%, while doxorubicinPlease cite this article in press as: Yu D-S, et al., Comparison of therapeu
cancer, Urological Science (2016), http://dx.doi.org/10.1016/j.urols.2016.0decreased tumor volume by ~30% with the same therapeutic
dosage at 60 days (p ¼ 0.01, Figure 4B).
Serial monitoring of the survival of mice in three groups showed
that the Lipodox group had a 60-day survival rate of 57%, while the
doxorubicin group had 43% and the control group had 25%.
Although it was not signiﬁcant (p ¼ 0.17 and 0.46 in each), mice
treated with Lipodox had longer survival than doxorubicin and
control mice (Figure 4C).
4. Discussion
Doxorubicin is one of the most commonly used broad-spectrum
chemotherapeutic drugs. Doxorubicin has been applied clinically
for years to prevent bladder tumor recurrence by intravesical
instillation, with an average response rate of 45%. Unfortunately, its
efﬁcacy is limited by the short intracellular retention with lower
applicable dosage due to its dose-dependent cardiotoxicity, which
may lead to the development of irreversible cardiomyopathy and/
or heart failure.5
Encapsulation of doxorubicin in PEG-coated liposomes was
developed to enhance the safety and efﬁcacy of conventional
doxorubicin. The liposomes alter pharmacological and pharmaco-
kinetic parameters of conventional doxorubicin so that drug de-
livery to the tumor is enhanced while toxicity of conventional
doxorubicin is decreased. In animals and humans, pharmacokinetic
advantages of Lipodox include an increased area under the plasma
concentrationetime curve, longer distribution half-life, smaller
volume of distribution, and reduced clearance.6
In preclinical models, Lipodox produced remission and cure
against many cancers including tumors of the breast, lung, ovaries,
prostate, colon, bladder, and pancreas, as well as mesothelioma,
lymphoma, sarcoma, and myeloma.7e13 It was also found to be
effective as adjuvant therapy with tolerable adverse reactions. In
addition, it was found to cross the bloodebrain barrier and induce
remission in tumors of the central nervous system. Currently, the
FDA has approved its use in patients with ovarian cancer, multiple
myeloma, and HIV-induced Kaposi's sarcoma.6 For prostate cancer,
Lipodox is effective in hypoxic xenografted tumors.14 For hormone-
refractory prostate cancer, Lipodox has undergone a Phase II study
showing limited activity and tolerable adverse reactions.15,16
Rozzi et al17 reported on using PLD as the third-line systemic
chemotherapy for patients with metastatic transitional cell carci-
noma of the urinary tract in a Phase II study. Three of 23 (13%)
patients presented a partial response, while 7 patients (30%)
showed stable disease for a disease control rate of 43%. Winquist
et al18 performed a similar trial with comparable results.
Increased potency over conventional doxorubicin was observed
and it was equally effective against low- and high-growth fraction
tumors.6 Combination of Lipodox with vincristine or trastuzumab
resulted in additive effects and possible synergy. Lipodox appears
to overcome multidrug resistance; possibly as the result of
increased intracellular concentrations and an interaction between
the liposome and P-glycoprotein function. Based on pharmacoki-
netic and preclinical studies, Lipodox, either alone or as part of
combination therapy, has potential applications to treat a variety of
cancers. Liposomal doxorubicin penetrates the cells rapidly, binds
to chromatin, and inhibits nucleic acid synthesis by intercalation
between adjacent base pairs of the DNA double helix, thus pre-
venting their unwinding for replication. Therefore, the tumor cell
cycle will be arrested at G0/G1 phase, and apoptosis followed the
arrest after long-term treatment of Lipodox in our preliminary
study (data not shown).
PLD was never evaluated as an intravesical regimen for super-
ﬁcial bladder cancer therapy. This study assessed the activity of PLD
in tumor cell lines and the therapeutic efﬁcacy in representativetic efﬁcacy of lipo-doxorubicin and doxorubicin in treating bladder
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Figure 2. The intracellular distribution of (A, B) doxorubicin (1.74 mg/mL) and (C, D) Lipodox (20 mg/mL) after drug treatment for 2 hours (A, C under contrast microscopic view; B, D
under ﬂuoroscopic view).
D.-S. Yu et al. / Urological Science xxx (2016) 1e64orthotopic bladder tumor of mice. Indeed, Lipodox has higher dose-
and time-dependent cytotoxicity than doxorubicin in TCC tumor
cells, although doxorubicin has higher initial cytotoxicity than
Lipodox. It indicates that Lipodox has better retentionwithin tumor
cells due to liposome-embedded pharmacokinetic function.Figure 3. Serial changes of intracellular drug ﬂuorescence of doxorubicin and Lipodox
in MBT-2 tumor cells after 2 hours treatment (24 hours, p < 0.05; 48 hours, p < 0.001).
Please cite this article in press as: Yu D-S, et al., Comparison of therapeu
cancer, Urological Science (2016), http://dx.doi.org/10.1016/j.urols.2016.0We used ﬁve urothelial cell carcinoma (UCC) cell lines, TSGH
8301, TSGH9202 (low-grade UCC), T24, J82, and MBT-2 (high-grade
UCC), initially to elucidate the sensitivity of doxorubicin and Lip-
odox using the MTT method (data not shown). The preliminary
results were similar in these cell lines. Therefore, we selected
TSGH8301 for further evaluation on the underlying mechanism of
Lipodox cytotoxicity.
The better cytotoxicity of Lipodox in TCC tumor cells can also be
attributed to the higher intracellular distribution and longer decay
duration of the drug. The size of Lipodox particles is
104.2 ± 28.3 nm, and enters the tumor cell via the endocytotic
pathway and subsequently undergo phagosome formation. In
contrast, doxorubicin enters tumor cells via diffusion.19 In this
study, we demonstrated that the main binding location of doxo-
rubicinwas the nuclei, while Lipodox binds primarily to the cellular
membrane, cytoplasmic phagosomes, and nuclear membrane after
drug treatment for 2 hours. We found that Lipodox had sevenfold
higher retention than doxorubicin at 48 hours after 2 hours treat-
ment. This indicates liposomal interaction with the cell membrane
and nuclear membrane during the process of endocytosis, allowing
for better retention in tumor cells and resulting in higher cyto-
toxicity than doxorubicin.
The orthotopic MBT-2 C3H mice bladder tumor model has been
well established at our laboratory since 1986. Usually, the incidence
of tumor occurrence is around 60e70% and various sizes of papil-
lary tumors are seen within the bladder cavity at 2e4 weeks aftertic efﬁcacy of lipo-doxorubicin and doxorubicin in treating bladder
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Figure 4. The gross and microscopic pictures of MBT-2 tumors in C3H mice bladder (A), wet weight of urinary bladder (B) and survival rate follow up (C) at 60 days after
doxorubicin and Lipodox treatment in MBT-2 orthotopic bladder tumor model in comparison with control group mice (p ¼ 0.04 and p ¼ 0.01 in each two groups comparison).
D.-S. Yu et al. / Urological Science xxx (2016) 1e6 5cancer cell instillation. Tumor occurrence is proved by histological
examination in each bladder specimen.We have also conﬁrmed the
better therapeutic efﬁcacy of intravesical instillation of Lipodox
over doxorubicin in treating xenografted bladder tumor growth in
mice.
The effective cytotoxic dose of Lipodox starts from 16 mg/mL,
therefore, we chose intravesical therapy for orthotopic MBT-2
bladder cancer using 100 mL doxorubicin or Lipodox (160 mg/mL)
and retained for 1 hour. Currently, clinical usage of doxorubicin for
intravesical therapy usually is 30e40 mg/50 mL, thus, we believe
the dosewe applied tomicewas appropriate and even lower than in
the clinical situation. The tumor size markedly decreased in
Lipodox-treated mice compared with doxorubicin-treated mice,
with increased survival rate. It indicates that intravesical instillation
of Lipodox is tolerable and safe for hosts with this therapeutic dose.
Regarding the cardiocytotoxicty of doxorubicin- and Lipodox-
treated mice, we found that Lipodox-treated mice were free of
cardiocytotoxic side effects as doxorubicin-treated mice had a
28.6% incidence of cardiocytotoxic side effects with inﬂammation
of cardiac muscle cells in this study (data not shown).
5. Conclusion
We have demonstrated the differences in intracellular distri-
bution pathways between Lipodox and doxorubicin, which givesPlease cite this article in press as: Yu D-S, et al., Comparison of therapeu
cancer, Urological Science (2016), http://dx.doi.org/10.1016/j.urols.2016.0Lipodox superior cytotoxic efﬁcacy in transitional cell carcinoma
cells and greater therapeutic effect and marginal survival beneﬁt in
orthotopic neogrowth of mice. These results may provide a useful
basis for further study of Lipodox as an alternative intravesical
therapeutic regimen for bladder cancer in clinical patients.
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